American Journal of Ophthalmology
Volume 143, Issue 2 , Pages 335-338, February 2007

Anti-VEGF Bevacizumab (Avastin®) for Radiation Optic Neuropathy

  • Paul T. Finger, MD

      Affiliations

    • Corresponding Author InformationInquiries to Paul T. Finger, MD, The New York Eye Cancer Center, 115 East 61st Street, New York City, New York, 10021

New York Eye Cancer Center, New York, New York.

Accepted 1 September 2006. published online 23 October 2006.

Purpose

To evaluate intravitreal bevacizumab treatment for radiation optic neuropathy (RON).

Design

Interventional case report.

Methods

At The New York Eye Cancer Center, a patient symptomatic of decreased vision because of RON was treated with intravitreal bevacizumab (1.25 mg). Main outcome measures included visual acuity, appearance of the optic nerve, fundus photography, angiography, and optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO).

Results

Within one week, her vision improved from 20/32 to 20/20 with a reduction in optic disk hemorrhage. At six weeks, evidence of both decreased hemorrhage and optic disk edema was documented by photography, angiography, and OCT/SLO. At the three and five-month follow-up visits, the hemorrhages resolved, and her disk margins were sharp. There were no ocular or systemic side effects.

Conclusions

Intravitreal bevacizumab was tolerated, improved vision, and reduced hemorrhage as well as optic disk edema (angiographic leakage). Anti-VEGF therapy (e.g. bevacizumab) should be investigated for both ocular and nonocular radiation neuropathy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported in part by a Grant from John and Myrna Daniels, Toronto, Ontario, Canada, and The EyeCare Foundation, New York, New York. The author indicates no financial conflict of interest. The author was involved in collection, management, analysis and interpretation of data, and preparation of the data and revision including references; involved in collection of data; and involved in management, statistical analysis and interpretation of the data, and preparation of the manuscript.

PII: S0002-9394(06)01067-1

doi:10.1016/j.ajo.2006.09.014

American Journal of Ophthalmology
Volume 143, Issue 2 , Pages 335-338, February 2007

Article Tools

* Image Usage & Resolution